Rituximab in Neuromyelitis Optica Spectrum Disorders: Why Not as First-Line Therapy.
Department of Neurology, Research Institute and Hospital of National Cancer Center, South Korea.
Su-Hyun
SH
Kim
Department of Neurology, Research Institute and Hospital of National Cancer Center, South Korea.
Ho Jin
HJ
Kim
D006801:Humans; D007155:Immunologic Factors; D009471:Neuromyelitis Optica; D000069283:Rituximab
D007155:Immunologic Factors; D000069283:Rituximab